A retrospective study of intravenous pentamidine for Pneumocystis jirovecii pneumonia prophylaxis in adult patients with hematologic malignancies —its utility during respiratory virus pandemics
In hematology, prophylaxis for Pneumocystis jirovecii pneumonia (PCP) is recommended for patients undergoing hematopoietic stem cell transplantation (HSCT) and in selected categories of intensive chemotherapy for hematologic malignancies (HMs) [1]. Trimethoprim-sulfamethoxazole (TMP-SMX) is the recommended first-line agent; however, its use is not straightforward because it can be associated with myelosuppression and elevation of potassium and creatinine [2]. Furthermore, many patients have a sulfa allergy and some are glucose-6-phosphate dehydrogenase –deficient [3].
Source: International Journal of Infectious Diseases - Category: Infectious Diseases Authors: Yi Xin Liew, Aloysius Yew Leng Ho, Gee Chuan Wong, Shimin Jasmine Chung, Thuan Tong Tan, Ban Hock Tan Tags: Short Communication Source Type: research
More News: Allergy | Allergy & Immunology | Bactrim | Cancer & Oncology | Chemotherapy | G6PD | Hematology | Infectious Diseases | Pandemics | Pneumonia | Potassium | Respiratory Medicine | Stem Cell Therapy | Stem Cells | Study | Sulfamethoxazole | Transplants | Trimethoprim